Natpar (Parathyroid Hormone)

Parathyroid hormone (1-84), the active ingredient in Natpar, is a parathyroid hormone analog presented as a subcutaneous injectable for subcutaneous use. It is indicated for the treatment of hypoparathyroidism, helping to restore normal serum calcium levels in affected patients.

GNH USA supplies Natpar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Clients benefit from consistent product availability and regulatory support across multiple regions.

Natpar, a parathyroid hormone analog, is used to manage disorders of calcium metabolism associated with hypoparathyroidism. - Hypoparathyroidism: raises and maintains serum calcium levels in patients with chronic disease. - Post‑surgical hypoparathyroidism: supports calcium homeostasis after thyroid or parathyroid gland surgery. - Chronic hypoparathyroidism: provides long‑term regulation of calcium balance when endogenous PTH is deficient.

Parathyroid hormone therapy may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Injection site reactions: redness, swelling or pain. - Hypercalcemia: mild elevation of serum calcium.

Serious or Rare Side Effects: - Severe hypercalcemia: may lead to cardiac arrhythmia or renal dysfunction. - Osteosarcoma: theoretical risk based on animal data. - Anaphylaxis: rare allergic reaction requiring emergency care.

When using Natpar, several precautions should be observed to ensure safety and therapeutic effectiveness. - Monitor serum calcium: regular laboratory testing to avoid hypercalcemia. - Assess vitamin D status: ensure adequate levels before initiating therapy. - Adjust dose in renal impairment: reduced clearance may increase calcium levels. - Avoid use in existing hypercalcemia: contraindicated when calcium is already elevated. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Parathyroid hormone can interact with other agents that affect calcium balance or bone metabolism.

Major Interactions (Avoid): - Calcium supplements: may cause excessive hypercalcemia. - Active vitamin D analogs (calcitriol, alfacalcidol): additive increase in calcium levels. - Thiazide diuretics: enhance renal calcium reabsorption, raising risk of hypercalcemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter calcium excretion, requiring dose adjustment. - Bisphosphonates: opposite effect on bone turnover, may reduce efficacy. - Magnesium supplements: high levels can interfere with PTH activity.